Maiwei Biotechnology (688062.SH): The application for clinical trials of 9MW3811 injection has been approved by the National Medical Products Administration.

Zhtng Cijng APP News, Maiwei Biological (688062.SH) announced that recently, the company has received the "Notice of Approval for Clinical Trial of Drugs" issued by the National Medical Products Administration. The application for Phase II clinical trial of 9MW3811 Injection for the indication of pathological scars has been approved.